Human bone marrow myeloma cells express RANKL.

Abstract

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.1.353 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11773196 Human Bone Marrow Myeloma Cells Express RANKL Orhan SezerxOrhan SezerSearch for articles by this author , Ulrike HeiderxUlrike HeiderSearch for articles by this author , Christian JakobxChristian JakobSearch for articles by this author , Jan EuckerxJan EuckerSearch for articles by this author , Kurt PossingerxKurt PossingerSearch for articles by this author G. David RoodmanxG. David RoodmanSearch for articles by this author Show More Universitätsklinikum Charité, Berlin, GermanyUniversity of Texas Science Center at San Antonio, San Antonio, TX https://doi.org/10.1200/JCO.2002.20.1.353 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical OncologyjcoJ Clin OncolJournal of Clinical OncologyJCO0732-183X1527-7755American Society of Clinical OncologyResponse01012002In Reply:Thank you for your letter. Several groups, including the data you have provided, have found that myeloma cells themselves express receptor activator of NF-kappaB ligand (RANKL), although the levels of RANKL expression have been variable. In contrast to the results that you report, others, such as Pearse et al,1 have not detected RANKL expression by myeloma cells in bone marrow biopsy specimens from patients with myeloma. These researchers found that RANKL was not expressed by myeloma cells in the 14 bone marrow biopsy specimens from myeloma patients they examined either by immunocytochemistry, in situ hybridization, or polymerase chain reaction. They found that RANKL expression was increased in multiple myeloma–infiltrated marrow but that RANKL was expressed by activated T cells and stromal cells and not by myeloma cells. Furthermore, they could not find RANKL expression by myeloma cell lines ARP-1, U266, RPM18226, H929, and ARH-77, as assessed by receptor activator of NF-kappaB (RANK)-Fc binding or by reverse transcriptase polymerase chain reaction. Although expression of RANKL by myeloma cells is shown very nicely by your results and those of others, it has not been a consistent finding by all investigators. The most consistent finding by most investigators is that RANKL expression is increased in marrow stromal cells from myeloma patients.REFERENCE1. Pearse RN, Sordillo EM, Yaccoby S, et al: Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 98:: 11581,2001-11586, Crossref, Medline, Google Scholar